Navigation Links
Bioartificial Kidney Cuts Death Risk, Improves Outcomes
Date:4/30/2008

In small study, device helped a little more than half of patients recover renal function

WEDNESDAY, April 30 (HealthDay News) -- Another successful clinical trial suggests that a bioartificial kidney to save the lives of people with acute renal failure will be available within a few years.

This latest study found that short-term replacement of renal cell function using the renal tubule assist device (RAD) -- the living cartridge that's critical to the function of the bioartificial kidney -- significantly reduced death risk and sped recovery of kidney function in patients with acute renal failure resulting from acute kidney injury.

The study of 58 critically ill patients, aged 18 to 80, found that the death rate after 28 days was 33 percent for patients who received continuous venovenous hemofiltration combined with RAD, compared to 66 percent for patients who received the more traditional continuous renal replacement therapy. At day 28, 53 percent of the patients in the RAD group had recovered renal function.

In the 180 days following treatment, patients in the RAD group had a 50 percent reduction in death risk. The study was published online in the Journal of the American Society of Nephrology.

"Our study results are encouraging, and they raise expectations that our new approach may yield a better treatment for life-threatening acute renal failure, for which a high mortality rate has remained unchanged [50 percent to 70 percent] despite years of advances in conventional therapies," study author Dr. H. David Humes, a professor of internal medicine at the University of Michigan School of Medicine, said in a prepared statement.

"Even more promising, the nature of our new approach -- using living cells as therapeutic agents -- argues for the feasibility of developing whole classes of new cell-based and tissue-engineered therapies," Humes said.

While this was a small study, he said it offers encouragement that a related device -- a wearable kidney that performs natural functions -- can be developed in the near future to treat people with chronic renal failure.

"The ability to harness vital processes of cells, to target their living molecular machinery on restoring critical substances which have become disordered by disease, has vast implications for the future of medicine," Humes said. "The apparently successful use of living cells in this way validates our approach and should encourage others to investigate cell therapies for a range of disorders."

He and his colleagues started developing the bioartificial kidney more than a decade ago. The device includes a cartridge that filters the blood as in traditional kidney dialysis. The cartridge is connected to the RAD, which is made of hollow fibers lined with a type of kidney cell called renal proximal tubule cells, which reclaim vital electrolytes, salt, glucose and water, and control production of immune system molecules called cytokines, which fight infection.

More information

The American Academy of Family Physicians has more about kidney failure.



-- Robert Preidt



SOURCE: University of Michigan Health System, news release, April 24, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Kidney Care Community Applauds National Taxpayers Unions Endorsement of Medicare Reforms to Extend Patient Private Health Insurance Coverage; Calls Proposal Common Sense Coverage Reform
2. Cutting Phosphate May Protect Kidney Patients From Heart Trouble
3. Muscle Mass May Not Explain High Creatinine in Black Kidney Patients
4. Readily available treatment could help prevent heart disease in kidney patients
5. Study Points to New Treatments for Polycystic Kidney Disease
6. Raloxifene Safe for Women With Decreased Kidney Function
7. Kidney cancer deaths show overall decrease in Europe
8. Diplomat Specialty Pharmacy Hires National Accounts Director To Expand Kidney Disease Services
9. Northwestern Memorial Successfully Completes Rare Four-Way Domino Paired Kidney Exchange Transplant Surgery
10. Kidney Community Gathers on Capitol Hill to Ask Congress to Support Legislation for Increased Kidney Care Education, Updates for Kidney Dialysis Benefit
11. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 2017 , ... ProRehab Physical Therapy (PRPT) is ... therapy provider for Derby City CrossFit, effective immediately. , In addition to treating ... effectively as possible, ProRehab’s sports physical therapists will work with athletes to maximize ...
(Date:4/25/2017)... ... 2017 , ... A recent report from the Wisconsin Institute ... 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools participating ... student test score performance, the report’s limited analyses fail to provide answers as ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... ... 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of ... I focus on preventative care with all my patients to alleviate possible future issues. I ... free to contact my office and my trained staff will assist you in any way ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
Breaking Medicine Technology: